Physician profile
Manish Kumar
NPI 1285085761
$739.59
in general payments reported to CMS, 2019-2025
9 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $316 · 2023: $90.35 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333 · Education: $90.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.31 |
| Education | $90.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.00 | 2025 | Repatha, Repatha |
| Abbott Laboratories | $116.62 | 2022 | |
| Lantheus Medical Imaging, INC. | $93.41 | 2022 | |
| Medtronic, INC. | $90.35 | 2023 | Micra |
| Astrazeneca Pharmaceuticals Lp | $87.45 | 2022 | |
| Pfizer INC. | $66.26 | 2022-2025 | |
| Abiomed | $62.07 | 2025 | |
| Bridgebio Pharma, INC. | $56.04 | 2025 | Attruby |
| Angiodynamics, INC. | $17.39 | 2025 | Alphavac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.